Coronary bifurcation lesions pose therapeutic problems during percutaneous coronary
interventions (PCI) and are associated with higher rates of periprocedural complications as
well as higher rates of in-stent restenosis and stent thrombosis. Provisional T-stenting
(PTS) is the best treatment strategy at the moment. However, the optimal approach to coronary
bifurcations treatment is still a subject of debate, especially when the side branch is
large, not easily accessible and narrowed by a long lesion. One of the proposed alternatives
are dedicated bifurcation stents (DBS). However, there is large scarcity of randomized trials
with DBS. POLBOS II study is continuation of POLBOS I (POLish Bifurcation Optimal Stenting)
study, in which paclitaxel-eluting stent BiOSS Expert® (Balton, Poland) was assessed. Now
performance of sirolimus-eluting stent BiOSS LIM® (Balton, Poland) is verified.
Phase:
Phase 4
Details
Lead Sponsor:
Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland